Operational Factors Associated With National Guideline Adherence to Vaso-Occlusive Crisis Management in the Emergency Department
Abstract
Objectives The National Heart, Lung, and Blood Institute guidelines for sickle cell disease (SCD) vaso-occlusive crisis (VOC) management recommend emergency departments (EDs) rapidly assess pain and administer pain medication following an individual’s arrival. An ED’s experience treating SCD along with co-occurring operational factors may affect guideline adherence. We investigated the effect of operational factors on VOC guideline adherence within a large New Jersey health system. Methods Electronic health record data between January 2022 and September 2025 were analyzed. Outcomes: rate of guideline-concordance, time-to-first and time-to-second pain medication administration. Adherence was defined as first dose ≤30 minutes after triage and second dose ≤30 minutes after first. Predictors: SCD patient volume, ED volume, shift, and emergency severity index (ESI) score. Descriptive and mixed-effects regression analyses were conducted. Results There were 7160 ED visits by 1401 patients. 14.2% of encounters were adherent for first pain medication, and 52.6% for second. SCD volume, ED volume, shift, and ESI score were associated with guideline-concordant encounter rates, but not site-level decreased average times. Shift timing was the only exposure significantly associated with mean times to both first and second pain medication administration. Individuals arriving during the evening shift received their first pain medication 15.93 minutes later (95% CI: 2.43 to 29.37) and their…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.